Evaluation of RIX4414, A Live, Attenuated Rotavirus Vaccine, in a Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Trial Involving 2464 Singaporean Infants | Zendy

Kong Boo Phua | Zendy; Seng Hock Quak | Zendy; Bee Wah Lee | Zendy; Shanta Emmanuel | Zendy; P. Goh | Zendy; Htay Htay Han | Zendy; Béatrice De Vos | Zendy; Hans L. Bock | Zendy

Open Access

Evaluation of RIX4414, A Live, Attenuated Rotavirus Vaccine, in a Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Trial Involving 2464 Singaporean Infants

Author(s) -

Kong Boo Phua,

Seng Hock Quak,

Bee Wah Lee,

Shanta Emmanuel,

P. Goh,

Htay Htay Han,

Béatrice De Vos,

Hans L. Bock

Publication year - 2005

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/431511

Subject(s) - reactogenicity , medicine , seroconversion , rotavirus vaccine , immunogenicity , placebo , rotavirus , vaccination , virology , diarrhea , pediatrics , immunology , virus , antibody , alternative medicine , pathology

At present, no rotavirus vaccine is commercially available for use worldwide. Hence, a live, attenuated monovalent vaccine was developed with human strain RIX4414 (G1P1A P[8] specificity). Vaccination trials involving infants are ongoing in developed and developing countries.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research